Efficacy and safety analysis of TACE + PEI + lenvatinib compared with TACE + lenvatinib for the treatment of hepatocellular carcinoma with PVTT: a retrospective study
ObjectiveThe aim of this study was to investigate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with percutaneous ethanol injection (PEI) and lenvatinib in HCC patients with PVTT (Vp2-3), thus providing a safe and effective treatment strategy for advanced HCC pa...
| Principais autores: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado em: |
Frontiers Media S.A.
2024-01-01
|
| coleção: | Frontiers in Oncology |
| Assuntos: | |
| Acesso em linha: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1280837/full |
| _version_ | 1827380413515956224 |
|---|---|
| author | Haohao Lu Haohao Lu Chuansheng Zheng Chuansheng Zheng Bin Liang Bin Liang Xiangwen Xia Xiangwen Xia Hongjie Fan Hongjie Fan |
| author_facet | Haohao Lu Haohao Lu Chuansheng Zheng Chuansheng Zheng Bin Liang Bin Liang Xiangwen Xia Xiangwen Xia Hongjie Fan Hongjie Fan |
| author_sort | Haohao Lu |
| collection | DOAJ |
| description | ObjectiveThe aim of this study was to investigate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with percutaneous ethanol injection (PEI) and lenvatinib in HCC patients with PVTT (Vp2-3), thus providing a safe and effective treatment strategy for advanced HCC patients.Materials and methodsClinical data of 227 patients with unresectable HCC and PVTT treated at the Union Hospital from January 2018 to December 2021 were retrospectively analyzed. The patients were divided into two groups according to their treatment methods: TACE+PEI+lenvatinib group (N=103) and TACE+lenvatinib group (N=124).ResultsThe proportion of patients with disappearance, shrinkage, or no change of PVTT after treatment was significantly higher in the TACE+PEI+lenvatinib group compared to the TACE+lenvatinib group, with statistical significance (P<0.001). The TACE+PEI+lenvatinib group had higher objective response rate (ORR) (50.5% vs. 25.8%, P<0.001) and disease control rate (DCR) (87.4% vs. 74.2%, P=0.013) than the TACE+lenvatinib group. The median progression-free survival (mPFS) of the TACE+PEI+lenvatinib group was longer than that of the TACE+lenvatinib group (8.1 months vs. 6.5 months, P<0.001). Consistently, the median overall survival (mOS) of the TACE+PEI+lenvatinib group was longer than that of the TACE+lenvatinib group (17.1 months vs. 13.9 months, P<0.001).ConclusionAmong HCC patients with PVTT (Vp2-3), TACE+PEI+lenvatinib is more effective comparing to TACE+lenvatinib in prolonging PFS and OS. The control of PVTT in the TACE+PEI+lenvatinib group was significantly more satisfactory than that in the TACE+lenvatinib group. TACE+PEI+lenvatinib is a safe and effective treatment strategy for HCC patients with PVTT (Vp2-3). |
| first_indexed | 2024-03-08T13:33:24Z |
| format | Article |
| id | doaj.art-6c1f4bc793bc4284843af731c943fbc5 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-08T13:33:24Z |
| publishDate | 2024-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-6c1f4bc793bc4284843af731c943fbc52024-01-17T04:37:59ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-01-011410.3389/fonc.2024.12808371280837Efficacy and safety analysis of TACE + PEI + lenvatinib compared with TACE + lenvatinib for the treatment of hepatocellular carcinoma with PVTT: a retrospective studyHaohao Lu0Haohao Lu1Chuansheng Zheng2Chuansheng Zheng3Bin Liang4Bin Liang5Xiangwen Xia6Xiangwen Xia7Hongjie Fan8Hongjie Fan9Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Province Key Laboratory of Molecular Imaging, Wuhan, ChinaDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Province Key Laboratory of Molecular Imaging, Wuhan, ChinaDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Province Key Laboratory of Molecular Imaging, Wuhan, ChinaDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Province Key Laboratory of Molecular Imaging, Wuhan, ChinaDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaHubei Province Key Laboratory of Molecular Imaging, Wuhan, ChinaObjectiveThe aim of this study was to investigate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with percutaneous ethanol injection (PEI) and lenvatinib in HCC patients with PVTT (Vp2-3), thus providing a safe and effective treatment strategy for advanced HCC patients.Materials and methodsClinical data of 227 patients with unresectable HCC and PVTT treated at the Union Hospital from January 2018 to December 2021 were retrospectively analyzed. The patients were divided into two groups according to their treatment methods: TACE+PEI+lenvatinib group (N=103) and TACE+lenvatinib group (N=124).ResultsThe proportion of patients with disappearance, shrinkage, or no change of PVTT after treatment was significantly higher in the TACE+PEI+lenvatinib group compared to the TACE+lenvatinib group, with statistical significance (P<0.001). The TACE+PEI+lenvatinib group had higher objective response rate (ORR) (50.5% vs. 25.8%, P<0.001) and disease control rate (DCR) (87.4% vs. 74.2%, P=0.013) than the TACE+lenvatinib group. The median progression-free survival (mPFS) of the TACE+PEI+lenvatinib group was longer than that of the TACE+lenvatinib group (8.1 months vs. 6.5 months, P<0.001). Consistently, the median overall survival (mOS) of the TACE+PEI+lenvatinib group was longer than that of the TACE+lenvatinib group (17.1 months vs. 13.9 months, P<0.001).ConclusionAmong HCC patients with PVTT (Vp2-3), TACE+PEI+lenvatinib is more effective comparing to TACE+lenvatinib in prolonging PFS and OS. The control of PVTT in the TACE+PEI+lenvatinib group was significantly more satisfactory than that in the TACE+lenvatinib group. TACE+PEI+lenvatinib is a safe and effective treatment strategy for HCC patients with PVTT (Vp2-3).https://www.frontiersin.org/articles/10.3389/fonc.2024.1280837/fullhepatocellular carcinomaportal vein tumor thrombuspercutaneous ethanol injectiontransarterial chemoembolizationmolecular targeted therapycomplications |
| spellingShingle | Haohao Lu Haohao Lu Chuansheng Zheng Chuansheng Zheng Bin Liang Bin Liang Xiangwen Xia Xiangwen Xia Hongjie Fan Hongjie Fan Efficacy and safety analysis of TACE + PEI + lenvatinib compared with TACE + lenvatinib for the treatment of hepatocellular carcinoma with PVTT: a retrospective study Frontiers in Oncology hepatocellular carcinoma portal vein tumor thrombus percutaneous ethanol injection transarterial chemoembolization molecular targeted therapy complications |
| title | Efficacy and safety analysis of TACE + PEI + lenvatinib compared with TACE + lenvatinib for the treatment of hepatocellular carcinoma with PVTT: a retrospective study |
| title_full | Efficacy and safety analysis of TACE + PEI + lenvatinib compared with TACE + lenvatinib for the treatment of hepatocellular carcinoma with PVTT: a retrospective study |
| title_fullStr | Efficacy and safety analysis of TACE + PEI + lenvatinib compared with TACE + lenvatinib for the treatment of hepatocellular carcinoma with PVTT: a retrospective study |
| title_full_unstemmed | Efficacy and safety analysis of TACE + PEI + lenvatinib compared with TACE + lenvatinib for the treatment of hepatocellular carcinoma with PVTT: a retrospective study |
| title_short | Efficacy and safety analysis of TACE + PEI + lenvatinib compared with TACE + lenvatinib for the treatment of hepatocellular carcinoma with PVTT: a retrospective study |
| title_sort | efficacy and safety analysis of tace pei lenvatinib compared with tace lenvatinib for the treatment of hepatocellular carcinoma with pvtt a retrospective study |
| topic | hepatocellular carcinoma portal vein tumor thrombus percutaneous ethanol injection transarterial chemoembolization molecular targeted therapy complications |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1280837/full |
| work_keys_str_mv | AT haohaolu efficacyandsafetyanalysisoftacepeilenvatinibcomparedwithtacelenvatinibforthetreatmentofhepatocellularcarcinomawithpvttaretrospectivestudy AT haohaolu efficacyandsafetyanalysisoftacepeilenvatinibcomparedwithtacelenvatinibforthetreatmentofhepatocellularcarcinomawithpvttaretrospectivestudy AT chuanshengzheng efficacyandsafetyanalysisoftacepeilenvatinibcomparedwithtacelenvatinibforthetreatmentofhepatocellularcarcinomawithpvttaretrospectivestudy AT chuanshengzheng efficacyandsafetyanalysisoftacepeilenvatinibcomparedwithtacelenvatinibforthetreatmentofhepatocellularcarcinomawithpvttaretrospectivestudy AT binliang efficacyandsafetyanalysisoftacepeilenvatinibcomparedwithtacelenvatinibforthetreatmentofhepatocellularcarcinomawithpvttaretrospectivestudy AT binliang efficacyandsafetyanalysisoftacepeilenvatinibcomparedwithtacelenvatinibforthetreatmentofhepatocellularcarcinomawithpvttaretrospectivestudy AT xiangwenxia efficacyandsafetyanalysisoftacepeilenvatinibcomparedwithtacelenvatinibforthetreatmentofhepatocellularcarcinomawithpvttaretrospectivestudy AT xiangwenxia efficacyandsafetyanalysisoftacepeilenvatinibcomparedwithtacelenvatinibforthetreatmentofhepatocellularcarcinomawithpvttaretrospectivestudy AT hongjiefan efficacyandsafetyanalysisoftacepeilenvatinibcomparedwithtacelenvatinibforthetreatmentofhepatocellularcarcinomawithpvttaretrospectivestudy AT hongjiefan efficacyandsafetyanalysisoftacepeilenvatinibcomparedwithtacelenvatinibforthetreatmentofhepatocellularcarcinomawithpvttaretrospectivestudy |